Your browser doesn't support javascript.
loading
Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
Milione, Massimo; Maisonneuve, Patrick; Grillo, Federica; Mangogna, Alessandro; Centonze, Giovanni; Prinzi, Natalie; Pusceddu, Sara; Garzone, Giovanna; Cattaneo, Laura; Busico, Adele; Bossi, Paola; Spaggiari, Paola; Pellegrinelli, Alessio; Del Gobbo, Alessandro; Ferrero, Stefano; Kankava, Ketevani; Pruneri, Giancarlo; Rolli, Luigi; Roca, Elisa; Bercich, Luisa; Tironi, Andrea; Benvenuti, Mauro Roberto; Gallazzi, Maria Sole; Romano, Rosalia; Berruti, Alfredo; Pastorino, Ugo; Capella, Carlo.
Afiliação
  • Milione M; First Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy, Massimo.milione@istitutotumori.mi.it.
  • Maisonneuve P; Division of Epidemiology and Biostatistics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Grillo F; Unit of Pathology, Department of Surgical Sciences and Integrated Diagnostics, University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy.
  • Mangogna A; Unit of Pathology, Clinical Department of Medical, Surgical and Health Science, University of Trieste, Ospedale di Cattinara, Trieste, Italy.
  • Centonze G; First Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
  • Prinzi N; Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Pusceddu S; Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
  • Garzone G; Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
  • Cattaneo L; First Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
  • Busico A; First Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
  • Bossi P; 2nd Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
  • Spaggiari P; Pathology Department, Humanitas Clinical and Research Center, Humanitas Milan ENETS Center of Excellence, Milan, Italy.
  • Pellegrinelli A; Pathology Department, Humanitas Clinical and Research Center, Humanitas Milan ENETS Center of Excellence, Milan, Italy.
  • Del Gobbo A; Department of Pathology, ASST Franciacorta, Mellino Mellini Hospital, Brescia, Italy.
  • Ferrero S; Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Kankava K; Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Pruneri G; Department of Biomedical Surgical and Dental Sciences, University of Milan, Milan, Italy.
  • Rolli L; Teaching, Scientific and Diagnostic Pathology Laboratory, Tbilisi State Medical University, Tbilisi, Georgia.
  • Roca E; 2nd Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
  • Bercich L; School of Medicine, University of Milan, Milan, Italy.
  • Tironi A; Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Benvenuti MR; Medical Oncology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
  • Gallazzi MS; Department of Pathology, ASST Spedali Civili of Brescia, Brescia, Italy.
  • Romano R; Department of Pathology, ASST Spedali Civili of Brescia, Brescia, Italy.
  • Berruti A; Thoracic Surgery Unit, Department of Medical and Surgical Specialties Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.
  • Pastorino U; Thoracic Surgery Unit, Department of Medical and Surgical Specialties Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.
  • Capella C; Thoracic Surgery Unit, Department of Medical and Surgical Specialties Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.
Neuroendocrinology ; 111(5): 475-489, 2021.
Article em En | MEDLINE | ID: mdl-32365350
ABSTRACT

BACKGROUND:

Little information is available concerning prognostic factors for bronchopulmonary large cell neuroendocrine carcinomas (BP-LCNECs) and even less is known about combined LCNECs (Co-LCNECs). We investigated whether an integrated morphological, immunohistochemical, and molecular approach could be used for their prognostic evaluation.

METHODS:

Morphological (including combined features), proliferative (mitotic count/Ki-67 index), immunohistochemical (napsin A, p40, TTF-1, CD44, OTP, SSTR2A, SSTR5, mASH1, p53, RB1, and MDM2), and genomic (TP53, RB1, ATM, JAK2, KRAS, and STK11) findings were analyzed in BP-LCNECs from 5 Italian centers, and correlated with overall survival (OS). The Ki-67 index was expressed as the percentage of positive cells in hot spots as indicated in the WHO 2019 Digestive System Tumors and, for Co-LCNECs, the Ki-67 index was evaluated only in the LCNEC component.

RESULTS:

A total of 111 LCNECs were distinguished into 70 pure LCNECs, 35 Co-LCNECs (27 with adenocarcinoma [ADC] and 8 with squamous cell carcinoma [SqCC]), and 6 LCNECs with only napsin A immunoreactivity. The Ki-67 index cutoff at 55% evaluated in the neuroendocrine component was the most powerful predictor of OS (log-rank p = 0.0001) in all LCNECs; 34 cases had a Ki-67 index <55% (LCNEC-A) and 77 had a Ki-67 index ≥55% (LCNEC-B). Statistically significant differences in OS (log-rank p = 0.0001) were also observed between pure and Co-LCNECs. A significant difference in OS was found between pure LCNECs-A and Co-LCNECs-A (p < 0.05) but not between pure LCNECs-B and Co-LCNECs-B. Co-LCNEC-ADC and LCNEC napsin A+ cases had longer OS than pure LCNEC and Co-LCNEC-SqCC cases (log-rank p = 0.0001). On multivariable analysis, tumor location, pure versus combined features, and napsin A, but no single gene mutation, were significantly associated with OS after adjustment for Ki-67 index and study center (p < 0.05).

CONCLUSIONS:

The Ki-67 proliferation index and the morphological characterization of combined features in LCNECs seem to be important tools for predicting clinical outcome in BP-LCNECs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Neuroendócrino / Carcinoma de Células Grandes / Antígeno Ki-67 / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Neuroendócrino / Carcinoma de Células Grandes / Antígeno Ki-67 / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article